drugset / Trial / NCT00377637

A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

NCT00377637

Phase 3 Completed 370 enrolled Hoffmann-La Roche Aspreva Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This 2 arm study assessed the efficacy of Mycophenolate Mofetil (MMF; CellCept) compared to cyclophosphamide in inducing a response in patients with lupus nephritis, and the long term efficacy of MMF compared to azathioprine in maintaining remission and renal function. Patients were randomized to receive either MMF (1.5 g twice daily \[bid\]) or cyclophosphamide (0.5-1.0 g/m\^2 in monthly pulses) in the induction phase. Those patients meeting criteria for response were re-randomized for entry into the maintenance phase, to receive either MMF (1 g bid) or azathioprine (2 mg/kg/day).

Timeline

Start
2005-07
Primary completion
2007-03
Completion
2010-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azathioprine Small molecule 2 mg/kg Oral
Comparator Cyclophosphamide Other / unclassified 1000 mg/m2 Intravenous
Subject Mycophenolate Mofetil Small molecule 1 g Oral
Subject Mycophenolate Mofetil Small molecule 1.5 g Oral
Background Prednisolone Other / unclassified 10 mg Oral

Indications